Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab

PURPOSE Durable partial response (PR) and durable stable disease (SD) are often seen in patients with hepatocellular carcinoma (HCC) receiving atezolizumab plus bevacizumab (atezo-bev).This study investigates the outcome of these patients and the histopathology of the residual tumors.PATIENTS AND The IMbrave150 study's atezo-bev group was analyzed.PR or SD per RECIST v1.1 METHODS lasting more than 6 months was defined as durable.For histologic analysis, a comparable real-world group of patients from Japan and Taiwan who had undergone resection of residual tumors after atezo-bev was investigated.RESULTS In the IMbrave150 study, 56 (77.8%) of the 72 PRs and 41 (28.5%) of the 144 SDs were considered durable.The median overall survival was not estimable for patients with durable PR and 23.7 months for those with durable SD.The median progression-free survival was 23.2 months for patients with durable PR and 13.2 months for those with durable SD.In the real-world setting, a total of 38 tumors were resected from 32 patients (23 PRs and nine SDs) receiving atezo-bev.Pathologic complete responses (PCRs) were more frequent in PR tumors than SD tumors (57.7% v 16.7%, P 5.034).PCR rate correlated with time from atezo-bev initiation to resection and was 55.6% (5 of 9) for PR tumors resected beyond 8 months after starting atezo-bev, a time practically corresponding to the durable PR definition used for IMbrave150.We found no reliable radiologic features to predict PCR of the residual tumors.CONCLUSION Durable PR patients from the atezo-bev group showed a favorable outcome, which may be partly explained by the high rate of PCR lesions.Early recognition of PCR lesions may help subsequent treatment decision.